Click here for slides on this topic


Cardiovascular safety study of the investigational GLP-1 receptor agonist, lixisenatide. ELIXA is an acronym for Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With Lixisenatide.
The following content matched the glossary term: ELIXA Expert Commentary Ed Horton, MD, on EMPA-REG OUTCOME Results


Ed Horton, MD, discusses EMPA-REG OUTCOME results: SGLT2 inhibitor, empagliflozin, cuts CV deaths in high-risk type 2 diabetes patients Expert Commentary Vivian Fonseca, MD, on EMPA-REG OUTCOME: Empagliflozin Cuts CV Deaths


Vivian Fonseca, MD, discusses the impact of EMPA-REG OUTCOME; SGLT2 inhibitor, empagliflozin, reduced cardiovascular deaths in high-risk type 2 diabetes patients

Empagliflozin Cuts Cardiovascular Deaths in Landmark Trial


The SGLT2 inhibitor, empagliflozin, reduces cardiovascular deaths in the EMPA-REG OUTCOME trial. Includes expert commentary. Expert Commentary Vivian Fonseca MD on Results of ELIXA the First Cardiovascular Safety Study to Report Outcomes With A GLP-1 Receptor Agonist


In this diabetes expert blog, Vivian Fonseca, MD, provides insights on results of the ELIXA cardiovascular safety study of the novel (at time of publishing) GLP-1 receptor agonist, lixisenatide.

ADA 2015: The 75th Scientific Sessions of the American Diabetes Association


Coverage of data from ADA 2015, June 5-9, 2015 in Boston, Massachusetts

Slide Library Results

Search Results for: ELIXA Slides Found: 2
ELIXA No Cardiovascular Risks Lixisenatide GLP-1 CV Safety | NDEI
ELIXA Cardiovascular Safety Outcomes for Lixisenatide GLP-1 | NDEI